4-(2-methyl-3-{4-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-1-yl}propyl)morpholine | 1202244-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 4-(2-methyl-3-{4-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-1-yl}propyl)morpholine
• 英文别名: 4-[2-Methyl-3-[4-[4-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-thiazol-2-yl]piperidin-1-yl]propyl]morpholine
• CAS: 1202244-11-8
• 化学式: C₃₀H₄₅N₃OS
• 分子量: 495.773
• InChiKey: PJAHVFHBXYFKTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  56.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-溴-1-(5,5,8,8-四氢萘)2-乙酮 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 17.0h， 生成 4-(2-methyl-3-{4-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-1-yl}propyl)morpholine
  参考文献：
  名称：

  THIAZOLYL PIPERIDINE DERIVATIVES

  摘要：

  式(I)的化合物中，其中R1、R2、R3、R4、R5、R6、R9、R10、R11、Q和W具有权利要求书中所示的含义，以及它们的前体是鞘氨醇激酶的抑制剂，可用于治疗肿瘤等用途。

  公开号：

  US20110105505A1

文献信息

• THIAZOLYL-PIPERIDINDERIVATE
  申请人：Merck Patent GmbH

  公开号：EP2313403B1

  公开（公告）日：2015-04-08
• COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS
  申请人：BROWN Dennis M.

  公开号：US20160067241A1

  公开（公告）日：2016-03-10

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.
• US8436186B2
  申请人：——

  公开号：US8436186B2

  公开（公告）日：2013-05-07
• [DE] THIAZOLYL-PIPERIDINDERIVATE<br/>[EN] THIAZOLYL PIPERDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE THIAZOLYL-PIPERIDINE
  申请人：MERCK PATENT GMBH

  公开号：WO2009156041A2

  公开（公告）日：2009-12-30

  Verbindungen der Formel (I) worin R1, R2, R3, R4, R5, R6, R9, R10, R11, Q und W die in Anspruch 1 angegebenen Bedeutungen haben und deren Vorstufen sind Inhibitoren der Sphingosinkinase und können u.a. zur Behandlung von Tumoren eingesetzt werden.
• [EN] COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'AMÉLIORER LE BÉNÉFICE THÉRAPEUTIQUE DES COMPOSÉS CHIMIQUES ADMINISTRÉS DE MANIÈRE SUBOPTIMALE COMPRENANT DES NAPHTALIMIDES SUBSTITUÉS TELS QUE L'AMONAFIDE POUR LE TRAITEMENT DES MALADIES IMMUNOLOGIQUES, MÉTABOLIQUES, INFECTIEUSES ET INFECTIEUSES OU HYPERPROLIFÉRATIVES ET NÉOPLASTIQUES.
  申请人：BROWN DENNIS M

  公开号：WO2014179528A2

  公开（公告）日：2014-11-06

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.